We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Jumping "DNA Parasites” Linked to Early Tumor Development

By LabMedica International staff writers
Posted on 12 Mar 2026

Cancer genomes accumulate complex structural variants that can be difficult to resolve with standard short-read sequencing, obscuring clinically relevant drivers of disease. More...

Transposable elements, particularly long interspersed nuclear element-1 (LINE-1), have been implicated in this instability, but their timing and impact have remained uncertain. Clarifying these mechanisms could inform which genomic analyses best capture the alterations shaping tumor evolution. New findings demonstrate that LINE-1 activity can trigger early, large-scale genome remodeling in tumors.

Investigators used long-read sequencing to resolve how LINE-1 (L1) retrotransposition restructures cancer genomes. Long-read sequencing enabled reconstruction of complex structural variation that short-read technologies struggle to assemble, revealing the full spectrum of L1-induced changes. L1 elements copy and insert themselves into new genomic loci, a process that can produce simple insertions as well as deletions, translocations, and other architectural rearrangements.

The team analyzed ten tumors with high L1 activity—five head and neck squamous carcinomas, four lung squamous carcinomas, and one colorectal adenoma—performing in-depth sequencing and variant interpretation. A total of 6,418 retrotransposition events were identified, the vast majority being insertions that extended genomic length, often as truncated copies. Crucially, 152 events produced large-scale structural rearrangements, with an estimated incidence of one in 40 among high-activity tumors and one in 60 in lower-activity tumors, underscoring their potential to drive oncogenesis.

The researchers report that two in three (65%) L1 events occurred during early tumor evolution. Whole genome doubling occurred a median of 4.77 years before diagnosis in this cohort, and most L1 activity preceded this milestone, indicating that retrotransposition can represent an early mutational process. They also observed that L1 promoters were typically less methylated in tumors than in nearby non-tumor tissue, consistent with epigenetic activation. Among the structural mechanisms, the group describes a previously unrecognized, balanced DNA exchange between chromosomes—termed a reciprocal translocation—likely arising from near-concurrent L1 events.

According to the report, these findings strengthen arguments for long-read sequencing in cases where standard tests cannot explain a tumor’s behavior, because short-read approaches may miss the underlying mechanism. The study was published in Science on February 6 and was carried out by CiMUS at the Universidade de Santiago de Compostela in collaboration with the Center for Genomic Regulation (CRG), Université Côte d'Azur, the Francis Crick Institute, and the University of Texas MD Anderson Cancer Center. The authors note that the cohort was deliberately seleted for extreme L1 activity, which may limit generalizability.

“Cancer genomes are more influenced by these jumping fragments of DNA parasites than we previously thought,” said Professor José Tubio, researcher at the Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS) at the Universidade de Santiago de Compostela (USC) and coordinator of the study.

“The next focus should be understanding when and where L1 activity tips the balance and how to target that therapeutically,” said Dr. Bernardo Rodriguez-Martin, Independent Fellow at the Center for Genomic Regulation in Barcelona and one of the main authors of the study.

Related Links
Center for Genomic Regulation (CRG)
CiMUS at the Universidade de Santiago de Compostela
 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.